EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT
Publication
, Conference
Hariharan, S; Kilic, C; Bowie, M; Reitman, Z; Ashley, D
Published in: NEURO-ONCOLOGY
2020
Duke Scholars
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2020
Volume
22
Start / End Page
279 / 279
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Hariharan, S., Kilic, C., Bowie, M., Reitman, Z., & Ashley, D. (2020). EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT. In NEURO-ONCOLOGY (Vol. 22, pp. 279–279).
Hariharan, Seethalakshmi, Cem Kilic, Michelle Bowie, Zachary Reitman, and David Ashley. “EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT.” In NEURO-ONCOLOGY, 22:279–279, 2020.
Hariharan S, Kilic C, Bowie M, Reitman Z, Ashley D. EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT. In: NEURO-ONCOLOGY. 2020. p. 279–279.
Hariharan, Seethalakshmi, et al. “EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT.” NEURO-ONCOLOGY, vol. 22, 2020, pp. 279–279.
Hariharan S, Kilic C, Bowie M, Reitman Z, Ashley D. EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT. NEURO-ONCOLOGY. 2020. p. 279–279.
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2020
Volume
22
Start / End Page
279 / 279
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences